Our results showed that Ang IV treatment did not affect serum lipid, glucose and blood pressure levels, indicating that the beneficial effect of Ang IV on diabetic cardiomyopathy cannot be attributed to metabolic and hemodynamic changes, which was consistent with our previous results of Ang-(1-7) treatment in a mouse model of diabetic cardiomyopathy 8, 9. The gene discussed is AGT; the disease is diabetic cardiomyopathy.